U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C10H13NO4.3H2O
Molecular Weight 476.4749
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHYLDOPA

SMILES

O.O.O.C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O.C[C@](N)(CC2=CC(O)=C(O)C=C2)C(O)=O

InChI

InChIKey=YKFCISHFRZHKHY-NGQGLHOPSA-N
InChI=1S/2C10H13NO4.3H2O/c2*1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6;;;/h2*2-4,12-13H,5,11H2,1H3,(H,14,15);3*1H2/t2*10-;;;/m00.../s1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C10H13NO4
Molecular Weight 211.2145
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Methyldopate hydrochloride [levo-3-(3,4-dihydroxyphenyl)-2-methylalanine, ethyl ester hydrochloride] is the ethyl ester of methyldopa, supplied as the hydrochloride salt with a molecular weight of 275.73. Methyldopate hydrochloride is more soluble and stable in solution than methyldopa and is the preferred form for intravenous use. Methyldopate hydrochloride is an alpha adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.

CNS Activity

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ALDOMET

Approved Use

INDICATION AND USAGE: Hypertension.

Launch Date

1962
Primary
ALDOMET

Approved Use

INDICATION AND USAGE: Hypertension.

Launch Date

1962
Primary
ALDOMET

Approved Use

INDICATION AND USAGE: Hypertension.

Launch Date

1962
Primary
Methyldopate hydrochloride

Approved Use

Hypertension, when parenteral medication is indicated. The treatment of hypertensive crises may be initiated with Methyldopate HCl Injection.

Launch Date

1995
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
771.3 ng/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.54 μg × h/mL
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5352.9 ng × h/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.28 h
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.6 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
85%
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLDOPA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.5 g single, oral
Dose: 2.5 g
Route: oral
Route: single
Dose: 2.5 g
Sources:
unknown, 19
n = 1
Health Status: unknown
Age Group: 19
Sex: M
Population Size: 1
Sources:
Other AEs: Coma...
Other AEs:
Coma (grade 1)
Sources:
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Disc. AE: Depression, Tiredness...
AEs leading to
discontinuation/dose reduction:
Depression (2 patients)
Tiredness (2 patients)
Diarrhoea (1 patient)
Rash (1 patient)
Blackout (1 patient)
Sources:
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Other AEs: Somnolence, Dry mouth...
Other AEs:
Somnolence (15 patients)
Dry mouth (12 patients)
Malaise (6 patients)
Constipation (5 patients)
Anorexia (5 patients)
Diarrhoea (3 patients)
Depression (2 patients)
Weight gain (2 patients)
Mental confusion (1 patient)
Postural hypotension (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Coma grade 1
2.5 g single, oral
Dose: 2.5 g
Route: oral
Route: single
Dose: 2.5 g
Sources:
unknown, 19
n = 1
Health Status: unknown
Age Group: 19
Sex: M
Population Size: 1
Sources:
Blackout 1 patient
Disc. AE
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Diarrhoea 1 patient
Disc. AE
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Rash 1 patient
Disc. AE
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Depression 2 patients
Disc. AE
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Tiredness 2 patients
Disc. AE
2326 mg multiple, oral (mean)
Recommended
Dose: 2326 mg
Route: oral
Route: multiple
Dose: 2326 mg
Sources:
unhealthy, 36-68
n = 30
Health Status: unhealthy
Condition: hypertension
Age Group: 36-68
Sex: M+F
Population Size: 30
Sources:
Mental confusion 1 patient
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Postural hypotension 1 patient
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Dry mouth 12 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Somnolence 15 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Depression 2 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Weight gain 2 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Diarrhoea 3 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Anorexia 5 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Constipation 5 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Malaise 6 patients
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy
n = 39
Health Status: unhealthy
Condition: hypertension
Sex: M+F
Population Size: 39
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Use of alpha-methyldopa in the treatment of arterial hypertension].
1975 Aug 31
Persistent parkinsonism following neuroleptanalgesia.
1975 May
Cardiac hypertrophy and antihypertensive therapy.
1977 Sep
Development and trends in the drug treatment of essential hypertension.
1992 Dec
Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex.
1992 Jul
Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands.
1999 Sep
Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?
2001
Pregnancy and renal failure: the case for application of dosage guidelines.
2001
Treating hypertension in women of child-bearing age and during pregnancy.
2001
Spectrophotometric determination of certain vicinal dihydroxybenzene derivatives in pharmaceutical preparations.
2001 Apr
[Drug-induced hemolytic anemia].
2001 Aug
Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies.
2001 Jul
Pharmacological treatment of severe hypertension in pregnancy and the role of serotonin(2)-receptor blockers.
2001 Mar
Pharmacokinetic and pharmacodynamic alterations of methyldopa in rats with aortic coarctation. A study using microdialysis.
2001 Nov
Juxtaglomerular cell tumor in pregnancy.
2001 Nov
The effects of nitric oxide synthase inhibitors on the sedative effect of clonidine.
2001 Nov
Catechol-O-methyltransferase (COMT) genetic polymorphism in a Turkish population.
2001 Sep
Involvement of imidazoline receptors in the baroreflex effects of rilmenidine in conscious rabbits.
2001 Sep
The immune haemolytic anaemias: a century of exciting progress in understanding.
2001 Sep
Excretion of antihypertensive medication into human breast milk: a systematic review.
2002
Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.
2002
Immune-mediated drug-induced liver disease.
2002 Aug
Calcium channel blocker, nimodipine, for the treatment of bipolar disorder during pregnancy.
2002 Dec
Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial.
2002 Feb 19
Preparation of (R) and (S) alpha methyldopa from a chiral hydantoin containing the alpha phenylethyl group.
2002 Feb-Mar
Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice.
2002 Jan
The effect of methyldopa treatment on uterine, umblical and fetal middle cerebral artery blood flows in preeclamptic patients.
2002 Jul
Detection of alpha-methyldopa on thin-layer plates using pi-acceptors in 1,4-dioxane.
2002 Jul-Aug
Antihypertensive medication compliance in a Veterans Affairs Healthcare System.
2002 Jun
Analysis of L-dopa in human serum.
2002 Nov
Nephropathic cystinosis associated with cardiomyopathy: a 27-year clinical follow-up.
2002 Nov 9
Oral beta-blockers for mild to moderate hypertension during pregnancy.
2003
Determination of antioxidant activity of some drugs using high-pressure liquid chromatography.
2003
Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
2003 Apr
Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
2003 Aug
Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat.
2003 Jan
Pharmacokinetic profile of methyldopa in the brain of sinaortic-denervated rats.
2003 Jul
[Circadian blood pressure rhythm in preeclampsia as a predictor of maternal and obstetrical outcome].
2003 Jul-Aug
Antihypertensive efficacy of moxonidine in primary care: a 'real-life' study.
2003 Jul-Aug
Blood pressure response to out-patient drug treatment of hypertension in 1973-1993 at Korle-Bu Teaching Hospital, Accra, Ghana.
2003 Jun
Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
2003 Jun
[Clinical observation on the efficacy enhancing and toxicity attenuating effect of nuzhen yangyin granule to the anti-parkinsonism therapy mainly with Medopa].
2003 Nov
Nocturnal sleep, daytime sleepiness, and quality of life in stable patients on hemodialysis.
2003 Nov 21
A survey of Canadian practitioners regarding the management of the hypertensive disorders of pregnancy.
2004
[Methyldopa in therapy of hypertension in pregnant women].
2004 Feb
Pheochromocytoma during pregnancy: laparoscopic and conventional surgical treatment of two cases.
2004 Feb
Oral enalapril-hydrochlorothiazide-methyldopa as first line treatment for severe hypertension in Nigerians.
2004 Jan
Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
2004 Jan-Feb
[Centrally-acting antihypertensive drugs].
2004 Mar
Drug-induced liver injury.
2004 Mar 1
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: When control has been obtained, oral therapy with tablets may be substituted for intravenous therapy, starting with the same dosage schedule used for the parenteral route. The effectiveness and anticipated responses are described in the circular for tablets.
Initial: 250 mg PO q8-12hr for 2 days, increase q2Days PRN Maintenance: 250-1000 mg/day divided q6-12hr PO, usually no more than 3 g/day IV (methyldopate): 250-1000 mg infusion over 30-60 minutes q6-8hr PRN; no more than 4 g/day
Route of Administration: Other
Human uterine microvascular endothelial cells (UtMVEC) (PromoCell, Heidelberg, Germany) were cultured in EGM-2- MV medium (Lonza, Basel, Switzerland) until about 80% confluent. Cells from passage 4-8 were used in this study. Tissue culture plates (24-wells) were coated with undiluted Matrigel (300 μL/well; In Vitro Technologies, Noble Park, Vic., Australia) and polymerized for 30 minutes at 37°C. UtMVECs (100 000 cells/well) were seeded into each well and endothelial cell tubular networks formed within 4 hours of further incubation at 37°C. HTR-8/ SVneo cells (100 000 cells/well) were then added to each well with or without a low dose of TNF-α (0.5 ng/mL) together with methyldopa (5 μg/ mL), labetalol (0.5 μg/mL), hydralazine (10 μg/mL) or clonidine (1.0 μg/ mL) and co-cultured with the endothelial cellular networks. The control co-cultured cells had neither TNF-α nor medications added. After 24 hours of culture, the cells were retrieved from the cellular networks in Matrigel with Cell Recovery Solution (CRS) (In Vitro Technologies) for RNA extraction
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:13:13 GMT 2023
Edited
by admin
on Fri Dec 15 15:13:13 GMT 2023
Record UNII
56LH93261Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYLDOPA
EP   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-IP  
USAN  
Official Name English
NSC-760080
Code English
ALDORIL COMPONENT METHYLDOPA
Common Name English
L-3-(3,4-DIHYDROXYPHENYL)-2-METHYLALANINE SESQUIHYDRATE
Common Name English
ALPHA-METHYLDOPA
Common Name English
DOPEGYT
Brand Name English
METHYLDOPUM [WHO-IP LATIN]
Common Name English
L-TYROSINE, 3-HYDROXY-.ALPHA.-METHYL-, SESQUIHYDRATE
Common Name English
L-TYROSINE, 3-HYDROXY-.ALPHA.-METHYL-, HYDRATE (2:3)
Systematic Name English
Methyldopa sesquihydrate [WHO-DD]
Common Name English
PRESINOL
Brand Name English
METHYLDOPA [USAN]
Common Name English
METHYLDOPA [USP-RS]
Common Name English
METHYLDOPA [USP MONOGRAPH]
Common Name English
METHYLDOPA [ORANGE BOOK]
Common Name English
METHYLDOPA [VANDF]
Common Name English
MK-351
Code English
METHYLDOPA SESQUIHYDRATE [MI]
Common Name English
METHYLDOPA SESQUIHYDRATE
MART.   MI   WHO-DD  
Common Name English
DOPAMET
Brand Name English
METHYLDOPA SESQUIHYDRATE [MART.]
Common Name English
METHYLDOPA [WHO-IP]
Common Name English
METHYLDOPA HYDRATE
JAN  
Systematic Name English
METHYLDOPA COMPONENT OF ALDORIL
Common Name English
METHYLDOPA [MART.]
Common Name English
MEDOPREN
Brand Name English
METHYLDOPA [EP MONOGRAPH]
Common Name English
ALDOMET
Brand Name English
METHYLDOPA HYDRATE [JAN]
Common Name English
Classification Tree Code System Code
WHO-VATC QC02AB01
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
LIVERTOX NBK548173
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
NCI_THESAURUS C270
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
FDA ORPHAN DRUG 548616
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
WHO-VATC QC02LB01
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
NCI_THESAURUS C66884
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
NDF-RT N0000175554
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 12.3
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
Code System Code Type Description
DRUG CENTRAL
1762
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
NSC
760080
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
EVMPD
SUB08867MIG
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
CHEBI
61058
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID5020863
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
DRUG BANK
DB00968
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
DAILYMED
56LH93261Y
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
PUBCHEM
38852
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
LACTMED
Methyldopa
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
RS_ITEM_NUM
1426002
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
ChEMBL
CHEMBL459
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
FDA UNII
56LH93261Y
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
NCI_THESAURUS
C47616
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
RXCUI
6876
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY RxNorm
MESH
D008750
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
MERCK INDEX
m7397
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
CAS
41372-08-1
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
METHYLDOPA
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY Description: White to yellowish white, fine powder or lumps; odourless. Solubility: Slightly soluble in water and ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Antihypertensive. Storage: Methyldopa should be kept in a well-closed container, protected from light. Definition: Methyldopa contains not less than 98.0% and not more than 101.0% of C10H13NO4, calculated with reference to the anhydrous substance.
EVMPD
SUB25993
Created by admin on Fri Dec 15 15:13:13 GMT 2023 , Edited by admin on Fri Dec 15 15:13:13 GMT 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY